Login to Your Account

More Development 'Unlikely' After Neurogen's RA Drug Phase II Miss

By Karen Pihl-Carey

Thursday, June 17, 2004
Another round of disappointing data for NGD 2000-1 caused Neurogen Corp.'s stock to drop nearly 19 percent Wednesday, and made further development of the product in rheumatoid arthritis an unlikely plan. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription